Press Release – Page 10 – I-Mab | Pioneering the Next Generation of Immuno-Oncology

2021.09.30

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab

2021.09.28

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

2021.09.13

I-Mab Added to FTSE ESG Index Series

2021.09.02

I-Mab Added to FTSE Russell Global Equity Index Series

2021.08.31

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021

2021.08.27

I-Mab Announces Upcoming Participation at September Conferences

2021.08.19

I-Mab Announces Establishment of Environmental, Social and Governance Committee

2021.08.17

I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021

2021.08.11

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19

2021.07.30

I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer’s Disease